Part 11 — When Cancer Returns
Chapter 25
Surveillance Protocol — Detecting Relapse Early
How to monitor effectively without being consumed by monitoring — follow-up schedules, tumor markers, and the specific symptoms that warrant urgent evaluation.
In This Chapter You Will Learn
- Standard surveillance schedules by cancer type for years 1–5 and beyond
- What tumor markers actually mean — and their important limitations
- Physical symptoms that warrant urgent evaluation vs. those that are normal recovery
- How to use liquid biopsy (ctDNA) as an emerging early-detection tool
Detecting relapse early — when tumor burden is small and localized — significantly expands treatment options and improves outcomes. But effective surveillance is not the same as constant scanning. Over-monitoring has real costs: radiation exposure, false positives requiring unnecessary procedures, and chronic anxiety that itself suppresses immune function. The goal is intelligent, protocol-driven monitoring.
Surveillance Schedules by Cancer Type
These schedules reflect general oncology guidelines — your individual schedule should be confirmed with your oncologist based on stage, treatment type, and specific risk factors.
| Cancer Type | Years 1–2 | Years 3–5 | Year 5+ | Primary Marker |
|---|---|---|---|---|
| Breast | Clinical exam + mammogram every 6–12 months | Annually | Annually | CEA, CA 15-3 (only if elevated at baseline; not routine without symptoms) |
| Colorectal | CEA every 3–6 months; colonoscopy at 1 year post-op | CEA every 6 months; CT abdomen/pelvis 6–12 months | Colonoscopy every 3–5 years | CEA — most useful for post-surgical monitoring |
| Ovarian | CA-125 + clinical exam every 3 months | Every 6 months | Annually | CA-125 — most sensitive for ovarian recurrence; monitor closely |
| Prostate | PSA every 3 months | PSA every 6 months | PSA annually | PSA — rising PSA = biochemical recurrence; requires imaging confirmation |
| Lung | CT thorax every 6 months + clinical exam | CT annually | CT annually or by symptoms | CEA (not all types; NSCLC adenocarcinoma most reliable) |
| Cervical | Pap/cytology + clinical exam every 3–6 months | Every 6 months | Annually | SCC-Ag (squamous cell carcinoma only; not routine) |
| Liver (HCC) | AFP + abdominal ultrasound every 3 months | Every 3–6 months | Every 6 months | AFP (not elevated in all HCC types; CT/MRI more sensitive) |
Understanding Tumor Markers — Opportunities and Limitations
| Marker | What Rising Levels May Indicate | Important Limitations |
|---|---|---|
| CEA | Colorectal, lung, breast activity | Elevated by smoking, infection, inflammatory bowel disease — single values less meaningful than trends |
| CA-125 | Ovarian cancer activity | Elevated by endometriosis, fibroids, pelvic inflammatory disease, and even menstruation |
| PSA | Prostate cancer activity after treatment | Can rise from benign prostatic hyperplasia; biochemical recurrence requires imaging confirmation before treatment |
| CA 15-3 | Breast cancer metastatic activity | Not sensitive enough for early detection; useful only if markedly elevated and trending upward |
| AFP | HCC or testicular germ cell tumor activity | Not elevated in all HCC subtypes; CT/MRI required for confirmation |
The Trend Matters More Than Any Single Value
A single marker value above reference range is far less meaningful than a consistent upward trend across 2–3 measurements. Single-value alarm is one of the primary causes of unnecessary follow-up procedures and anxiety. Ask your oncologist to show you your marker trend graph rather than a single number — the trajectory tells the clinical story.
Symptoms That Warrant Urgent Evaluation
Not every new symptom means relapse. But certain patterns require evaluation in days — not at the next scheduled appointment:
| Symptom | Potential Concern | First Step |
|---|---|---|
| New persistent bone pain (back, pelvis, ribs, long bones) | Bone metastasis | Contact oncologist within 48 hours — X-ray → bone scan or MRI |
| New persistent headache + visual changes or nausea | Brain metastasis | Same-day evaluation — warrants urgent MRI with contrast |
| Progressive shortness of breath without clear cause | Pleural effusion, lung metastasis, pulmonary embolism | Within 24 hours — chest X-ray → CT thorax |
| Unexplained weight loss >5% in 1 month | Active tumor metabolic activity | Within 1 week — full blood panel + multi-area imaging |
| Jaundice (yellow skin or eyes) | Liver metastasis or biliary compression | Same day — liver function panel + abdominal ultrasound |
| New painless lymph node enlargement persisting >4 weeks | Nodal recurrence or new disease | Within 1–2 weeks — ultrasound; biopsy if >1 cm and firm |
| Sudden abdominal enlargement or new ascites | Peritoneal metastasis or ovarian recurrence | Within 24–48 hours — ultrasound → CT |
Symptoms That Are Normal During Recovery
| Symptom | Why It Happens |
|---|---|
| Fatigue improving gradually | Normal post-treatment recovery — improving trend is the key signal |
| Mild joint pain from aromatase inhibitors | Known, expected side effect — discuss management with oncologist |
| Residual skin changes in radiation area | Expected post-radiation tissue changes — monitor for unusual changes |
| Improving foot tingling (CIPN) | Gradual nerve recovery — improvement over months is expected |
| Mild memory and concentration difficulty | Chemo brain — stable or improving course is expected; worsening course warrants evaluation |
Liquid Biopsy — An Emerging Surveillance Tool
Liquid biopsy detects circulating tumor DNA (ctDNA) fragments released by cancer cells into the bloodstream. A simple blood draw can — in principle — detect tumor activity before it shows on imaging.
Current status (2025): Several ctDNA tests are clinically available for specific cancers (colorectal, lung, breast). They are increasingly used to monitor treatment response and detect early recurrence. They are not yet standard of care for all cancer types, but their adoption is accelerating rapidly. Ask your oncologist: "Is there a ctDNA monitoring option appropriate for my cancer type?"
"Surveillance is not anxiety institutionalized. It is intelligence institutionalized — systematic, measured watching that gives you the earliest possible advantage."
Chapter 25 — Key Takeaways
- Detecting relapse early — when tumor burden is small and localized — meaningfully expands treatment options; this is the clinical purpose of surveillance scheduling.
- Tumor marker trends matter more than single values — a consistent upward trend across 2–3 measurements is the meaningful signal, not a single number above reference range.
- Seven specific symptoms warrant oncologist contact within 24–48 hours, not at the next scheduled appointment: new bone pain, new headache with neurological symptoms, progressive dyspnea, rapid weight loss, jaundice, new lymphadenopathy, and sudden ascites.
- Liquid biopsy (ctDNA) is an emerging surveillance tool increasingly available for common cancer types — ask your oncologist whether it is appropriate for your situation.